Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Hong Kong stocks finished lower on Friday, extending losses seen in previous sessions this week, as rate cut worries continue to dampen investor sentiment.
由於降息擔憂繼續抑制投資者情緒，香港股市週五收低，延續了本週前幾個交易日的跌勢。
The Hang Seng Index declined 1.38%, or 259.77 points, to close at 18,608.94. The Hang Seng China Enterprises Index fell 1.44%, or 96.54 points, to 6,605.24.
恒生指數下跌1.38％，跌幅259.77點，收於18,608.94點。恒生中國企業指數下跌1.44％，或96.54點，至6,605.24點。
In corporate news, Sunho Biologics (HKG:2898) made a strong trading debut in Hong Kong on Friday. The clinical-stage biotech firm closed at HK$14.52 per share, up by almost 8% from its IPO price of HK$13.50.
在企業新聞方面，三和生物製藥（HKG: 2898）週五在香港首次亮相，表現強勁。這家處於臨床階段的生物技術公司收於每股14.52港元，較其13.50港元的首次公開募股價格上漲了近8％。
Akeso's (HKG:9926) shares slumped nearly 23% at closing despite receiving marketing approval in China for its non-small cell lung cancer drug IVONESCIMAB.
儘管其非小細胞肺癌藥物IVONESCIMAB在中國獲得了上市許可，但Akeso（HKG: 9926）的股價在收盤時仍下跌了近23％。
Hong Kong-listed shares of China Vanke (HKG:2202, SHE:000002) dropped 9% after the real estate developer said it borrowed 20 billion yuan through a syndicated loan facility.
中國萬科（HKG: 2202，SHE: 000002）在香港上市的股票下跌了9％，此前該房地產開發商表示通過銀團貸款機制借入了200億元人民幣。
譯文內容由第三人軟體翻譯。